What is STRO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.24B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for STRO?

P/E (TTM) is n/a and 52-week range is $7.15 to $43.85 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s STRO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for STRO?

The company profile lists revenue (TTM) near $46M, net income (TTM) near $-18.06B, EPS (TTM) near $-17.32 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Sutro Biopharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 16.6M shares outstanding, ISIN US8693672011 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Sutro Biopharma Inc

$STRO

Health Care · Biotechnology

IR Run Scenarios

$14.27

-6.85%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 137 full-time employees. The company went IPO on 2018-09-27. The company designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.

Employees

133

Website

www.sutrobio.com/

IPO

2018-09-27

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)